Johnson & Johnson Innovation
VC Fund
Cambridge, United States
Johnson & Johnson Innovation is a VC fund in Cambridge focused on Biotechnology and Health Care. Johnson & Johnson Innovation accelerates early-stage innovation through strategic collaboration. It connects potential collaborators to resources with the goal of assisting them in advancing transformation science and technology across the pharmaceutical, medical device, and consumer healthcare spectrums.
- Total investments:
- 127
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Johnson & Johnson Innovation invests in
Stages Johnson & Johnson Innovation invests in
Countries Johnson & Johnson Innovation invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $5.1M–$67M
- Series B
- $10M–$150M
- Series C
- $30M–$103M
Investment Focus
Industry
- Biotechnology 53 (42%)
- Health Care 51 (40%)
- Medical 35 (28%)
- Therapeutics 26 (20%)
- Medical Device 22 (17%)
Stage
- Series A 31 (24%)
- Series B 29 (23%)
- Series C 17 (13%)
- Funding Round 12 (9%)
- Series D 6 (5%)
Country
- United States 55 (43%)
- Israel 6 (5%)
- Switzerland 4 (3%)
- United Kingdom 4 (3%)
- France 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chris Picariello
President
|
President | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Prazer Therapeutics
|
Prazer Therapeutics assists patients suffering from intractable diseases through the use of logical and innovative drug design approaches. They willaccomplished this through the use of new and innovative drug development platforms, such as rational molecular drug design technology and next-generation protein degradation technology. | $33.9M / Venture - Series Unknown / Jul 23, 2026 | |
TRIMTECH Therapeutics
|
TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M / Seed / Jun 23, 2026 | |
Fesarius Therapeutics
|
Fesarius Therapeutics is a biotechnology company that intends to develop and sell modified skin replacement products. To create a line of engineered tissue goods, developed a tissue engineering technique based on IP for microsphere-containing hydrogels. The company's method uses microspheres embedded in a collagen hydrogel to enhance thenumber of differential density interfaces that drive cell invasion into the scaffold, allowing patients to heal from trauma, burns, or infection at an affordable cost. | $20M / Series A / Jun 10, 2026 | |
SonoThera
|
SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M / Series B / Jun 10, 2026 | |
CereVasc
|
CereVasc is a medical device company that develops treatments for neurological diseases, with a primary focus on communicating hydrocephalus. The company is advancing the eShunt® System, an investigational device designed to manage cerebrospinal fluid through a minimally invasive endovascular approach rather than traditional open neurosurgery. Itstechnology includes an implantable cerebrospinal fluid shunt and associated delivery components intended to treat hydrocephalus while reducing the need for invasive surgical procedures. CereVasc conducts clinical studies to evaluate the safety and effectiveness of the eShunt System in patients with conditions such as normal pressure hydrocephalus and other forms of communicating hydrocephalus. The company’s work centers on developing device-based therapies that improve access to treatment for patients with neurological disorders. | $85M / Series C / Jun 04, 2026 | |
Mestag Therapeutics
|
Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology. | $40M / Venture - Series Unknown / Mar 17, 2026 | |
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M / Jan 27, 2026 | |
Distalmotion
|
Distalmotion is a medical device company founded and based in Lausanne, Switzerland. Our mission is to remove the complexity out of robotic surgery in order to establish a new standard of care, where all patients in general surgery, gynecology and urology have access to best-in-class minimally invasive care. To do so, we have developed a surgicalrobot called Dexter. Designed, developed and manufactured in Switzerland, Dexter integrates the benefits of laparoscopy and robotics. Dexter combines the affordability of laparoscopy with the benefits of robotics through his novel, on-demand approach to robotic surgery. For further information, visit: dexter.surgery and follow us on LinkedIn and Twitter: @Distalmotion. | Corporate Round / Jan 12, 2026 | |
EpiBiologics
|
EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M / Series B / Jan 08, 2026 | |
Link Cell Therapies
|
Link Cell Therapies develops engineered cell therapy technologies intended to create targeted CAR T-based treatments for cancer. The company applies proprietary logic-gating methods that require co-expression of multiple cancer antigens to activate therapeutic T cells, aiming to focus immune cell activity on tumor cells while reducing effects onnon-cancerous tissues. Its work spans programs for solid tumors and certain hematologic cancers, with lead candidates progressing through preclinical development and preparation for clinical research. Link Cell Therapies also explores additional platforms and therapeutic programs that build on its core targeting technology to expand applications of engineered cellular therapies. | $60M / Series A / Dec 15, 2025 | |
| See all 127 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Johnson & Johnson Innovation invest in?
Johnson & Johnson Innovation invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 127 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Johnson & Johnson Innovation's check size?
Johnson & Johnson Innovation typically joins rounds of $5.1M–$67M at Series A, $10M–$150M at Series B and $30M–$103M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Johnson & Johnson Innovation participates in.
How do I contact Johnson & Johnson Innovation?
Public channels for Johnson & Johnson Innovation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Johnson & Johnson Innovation?
The team at Johnson & Johnson Innovation includes Chris Picariello (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
